Magnesium Sulfate in the Prevention of Post-ERCP Pancreatitis.
Status:
Terminated
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
MagPEP is a multi-centre, randomized, phase III, double blind, placebo controlled, parallel
group trial. It evaluates magnesium sulfate for the prevention of post-ERCP pancreatitis.
Adult patients with a medical indication for ERCP are to be randomized (1:1 ratio) to receive
either magnesium sulfate or placebo (NaCl 0,9%) 60 min before and 6 hours after ERCP.